Project Grant R43CA247125

The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $678,228 project grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop GLISCAN, a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The project will optimize, verify, and validate the GLISCAN assay, which uses a highly sensitive digital PCR technology to quantify tumor...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $670,147 to Vanderbilt University Medical Center to conduct research aimed at improving the clinical sensitivity of circulating tumor DNA (ctDNA) liquid biopsies. The research program has three key objectives: 1) Elucidating the role of the RNA binding protein SAM68 in mediating cell-free DNA (cfDNA) release, 2) Pharmacologically optimizing cfDNA release and stability to...

This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,153 to Alelopharma Inc. to develop an ultra-sensitive liquid biopsy test to detect ALK gene fusions in non-small cell lung cancer patients. The goal is to create a diagnostic platform capable of accurately identifying ALK translocation variants in cell-free RNA from blood plasma, which could enable non-invasive cancer screening and monitoring of treatment response....

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $902,046 to Data Driven Bioscience Inc. to perform analytical and clinical validation of the extended applications for their DuoSeq genomic profiling assay. DuoSeq is a novel approach that enables dual DNA and RNA sequencing from a single workflow to provide comprehensive molecular diagnostic readouts for blood cancers, including DNA mutations, copy number alterations,...

The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $680,453 to the University of Wisconsin System to develop a liquid biopsy approach using circulating tumor DNA (ctDNA) fragments and machine learning to monitor for the transition between prostate adenocarcinoma and neuroendocrine prostate cancer (NEPC) in metastatic castration-resistant prostate cancer (mCRPC) patients. The key objectives are to: 1) determine if...

This $638,804 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Pennsylvania State University's Milton S. Hershey Medical Center aims to integrate cerebrospinal fluid (CSF) proteogenomic analyses to improve diagnosis and management of diffuse gliomas, the most common primary malignant adult brain tumors. The key objectives are to: 1) validate preliminary findings on CSF-based proteomic signatures that can differentiate diffuse...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...

This $649,486 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center aims to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The key objectives are to: Perform analytical validation of technologies for isolating large oncosomes (LO) from patient plasma samples for clinical use. Develop a multianalyte LO-based assay to detect lethal...